Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation
Authors
Keywords
NAFLD, Inflammation, PPARs
Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 75, Issue 16, Pages 2951-2961
Publisher
Springer Nature
Online
2018-05-22
DOI
10.1007/s00018-018-2838-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor γ
- (2018) Xueqing Zhong et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Non-Alcoholic Fatty Liver Disease
- (2018) Johannes Weiß et al. Deutsches Arzteblatt International
- Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries
- (2017) Qingsheng Liu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice
- (2017) Rodrigo Valenzuela et al. Lipids in Health and Disease
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease
- (2017) Wenjing Luo et al. Scientific Reports
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice
- (2016) Jelske N. van der Veen et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- Rosiglitazone protects rat liver against acute liver injury associated with the NF-κB signaling pathway
- (2016) Wei Chen et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD)
- (2016) Shyrlene Araújo et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt
- (2016) Yaoyao Jia et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- New insights into the multidimensional concept of macrophage ontogeny, activation and function
- (2016) Florent Ginhoux et al. NATURE IMMUNOLOGY
- Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression
- (2016) Enas A Abd El-Haleim et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease
- (2015) Sahar Mohamed El-Haggar et al. Hepatology International
- NAFLD: A multisystem disease
- (2015) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- Fenofibrate Treatment Attenuated Chronic Endoplasmic Reticulum Stress in the Liver of Nonalcoholic Fatty Liver Disease Mice
- (2015) Nan Zhang et al. PHARMACOLOGY
- LPSF/GQ-02 Inhibits the Development of Hepatic Steatosis and Inflammation in a Mouse Model of Non-Alcoholic Fatty Liver Disease (NAFLD)
- (2015) Amanda Karolina Soares e Silva et al. PLoS One
- Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease
- (2015) Hyun Jung Lee WORLD JOURNAL OF GASTROENTEROLOGY
- Physiological Functions of Peroxisome Proliferator-Activated Receptor β
- (2014) Jaap G. Neels et al. PHYSIOLOGICAL REVIEWS
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
- (2013) Melania Gaggini et al. Nutrients
- Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
- (2012) Mi Young Lee et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- Peroxisome Proliferator-activated Receptor α Positively Regulates Complement C3 Expression but Inhibits Tumor Necrosis Factor α-mediated Activation ofC3Gene in Mammalian Hepatic-derived Cells
- (2012) Denis A. Mogilenko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The natural carotenoid astaxanthin, a PPAR-α agonist and PPAR-γ antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes
- (2012) Yaoyao Jia et al. MOLECULAR NUTRITION & FOOD RESEARCH
- PPARs: Fatty acid sensors controlling metabolism
- (2012) Lars la Cour Poulsen et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation
- (2012) Radina Kostadinova et al. Cell and Bioscience
- Nonalcoholic fatty liver disease and bariatric surgery
- (2012) Sindu Stephen et al. Expert Review of Gastroenterology & Hepatology
- Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
- (2011) E. Boettcher et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells
- (2011) L. Serrano-Marco et al. DIABETOLOGIA
- The PPARβ/δ Activator GW501516 Prevents the Down-Regulation of AMPK Caused by a High-Fat Diet in Liver and Amplifies the PGC-1α-Lipin 1-PPARα Pathway Leading to Increased Fatty Acid Oxidation
- (2011) Emma Barroso et al. ENDOCRINOLOGY
- Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts
- (2011) Eva Morán-Salvador et al. FASEB JOURNAL
- Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction
- (2011) Paulina Pettinelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus
- (2011) Bengt Hamrén et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
- (2010) Giovanni Musso et al. ANNALS OF MEDICINE
- Interleukin-6 Signaling in Liver-Parenchymal Cells Suppresses Hepatic Inflammation and Improves Systemic Insulin Action
- (2010) F. Thomas Wunderlich et al. Cell Metabolism
- Licensing PPARγ to Work in Macrophages
- (2010) Claudio J. Villanueva et al. IMMUNITY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- (2010) Giovanni Targher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice
- (2010) Yue-Min Nan et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
- (2010) Beata Lecka-Czernik Current Osteoporosis Reports
- Kupffer cells in non-alcoholic fatty liver disease: The emerging view
- (2009) György Baffy JOURNAL OF HEPATOLOGY
- Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
- (2009) Robert R Henry et al. LANCET
- Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers
- (2009) M. A. Edens et al. Obesity Reviews
- Transcriptional profiling reveals divergent roles of PPARα and PPARβ/δ in regulation of gene expression in mouse liver
- (2009) Linda M. Sanderson et al. PHYSIOLOGICAL GENOMICS
- Pathogenesis of non-alcoholic fatty liver disease
- (2009) J. K. Dowman et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- THE ROLE OF ENDOGENOUS AND EXOGENOUS LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR-α) IN THE REGULATION OF INFLAMMATION IN MACROPHAGES
- (2009) Concetta Crisafulli et al. SHOCK
- Role of PPARs in Radiation-Induced Brain Injury
- (2009) Sriram Ramanan et al. PPAR Research
- Regulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
- (2008) Elena Rigamonti et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Integration of metabolism and inflammation by lipid-activated nuclear receptors
- (2008) Steven J. Bensinger et al. NATURE
- Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice
- (2008) Yue-Min Nan et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Ligand Activation of Peroxisome Proliferator–Activated Receptor β/δ (PPARβ/δ) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression
- (2008) Weiwei Shan et al. TOXICOLOGICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search